

Kevzara® (sarilumab) - New indication

- On June 11, 2024, <u>Regeneron and Sanofi announced</u> the FDA approval of <u>Kevzara (sarilumab)</u>, for treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients who weigh 63 kg or greater.
- Kevzara is also approved for the treatment of adults with:
 - Moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).
 - Polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.
- Use of Kevzara in pediatric patients with pJIA is supported by evidence from adequate and well-controlled studies of Kevzara in adults with RA, pharmacokinetic data from adult patients with RA, and pharmacokinetic comparability from study 4. Study 4 was an open-label, two-phase study in patients aged 2 to 17 years of age with pJIA who had an inadequate response to current therapy.
- Kevzara carries a boxed warning for risk of serious infections.
- The most common adverse reactions with Kevzara use for pJIA were nasopharyngitis, neutropenia, upper respiratory tract infection and injection site erythema.
- The recommended dose of Kevzara for the treatment of pJIA is 200 mg once every two weeks given as a subcutaneous injection (maximum dose 200 mg). Dosage in this patient population can be achieved by administering the 200 mg/1.14 mL pre-filled syringe.
 - The pre-filled pen is not intended for use in pediatric patients.
 - Kevzara is not approved in pediatric patients weighing less than 63 kg because of the lack of an appropriate dosage form.
- Refer to the Kevzara drug label for dosing for its other indications.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.